We are live on ! Find out more

484 hedge funds and large institutions have $8.28B invested in Sanofi in 2019 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 151 increasing their positions, 178 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

643% more call options, than puts

Call options by funds: $59.7M | Put options by funds: $8.04M

9% more capital invested

Capital invested by funds: $7.59B → $8.28B (+$693M)

10% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 51

0% more funds holding

Funds holding: 482484 (+2)

0.26% more ownership

Funds ownership: 14.01%14.27% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 88 (0)

15% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 178

Holders
484
Holders Change
+2
Holders Change %
+0.41%
% of All Funds
10.61%
Holding in Top 10
8
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
56
Increased
151
Reduced
178
Closed
51
Calls
$59.7M
Puts
$8.04M
Net Calls
+$51.7M
Net Calls Change
+$26.3M

SNY Hedge Fund Activity: Q3 2019 in Review

484 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q3 2019, worth a combined $8.28B — up 9.1% from $7.59B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new SNY positions and 51 closed out — a net gain of 5 holders — while 151 added to existing stakes and 178 trimmed.

The largest buyer was BlackRock, adding an estimated $120M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $128M.

  • 484 institutional investors held Sanofi (SNY) as of Q3 2019, up from 482 in Q2 2019.
  • Funds reported $8.28B of Sanofi stock for Q3 2019, up 9.1% quarter-over-quarter.
  • 56 funds opened new Sanofi positions in Q3 2019 and 51 closed out, a net change of +5 holders.
  • The largest Sanofi buyer in Q3 2019 was BlackRock, an estimated $120M added.
  • The largest Sanofi seller in Q3 2019 was Barrow, Hanley, Mewhinney & Strauss, an estimated $128M sold.

Based on aggregated 13F filings for Q3 2019.